• LAST PRICE
    112.5100
  • TODAY'S CHANGE (%)
    0.0000 (0.0000%)
  • Bid / Lots
    ---/ ---
  • Ask / Lots
    ---/ ---
  • Open / Previous Close
    0.0000 / 112.5100
  • Day Range
    ---
  • 52 Week Range
    Low 59.2200
    High 116.2500
  • Volume
    ---
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Monday's close: 111.98
TimeVolumeGKOS
09:32 ET2356111.73
09:56 ET503111.43
10:01 ET500111.495
10:03 ET100111.63
10:06 ET100111.9
10:08 ET100112.13
10:12 ET200112.38
10:19 ET300112.83
10:21 ET300112.8
10:24 ET2150112.465
10:30 ET100112.635
10:33 ET100112.46
10:35 ET220112.573
10:37 ET200112.5675
10:39 ET900112.12
10:46 ET100112.04
10:48 ET2247112.09
10:50 ET500112.31
10:51 ET1510112.315
10:53 ET796112.01
11:00 ET200112.055
11:04 ET500112.27
11:06 ET500112.255
11:08 ET400112.43
11:09 ET1037112.27
11:11 ET100112.225
11:15 ET328111.93
11:27 ET100111.78
11:29 ET100111.78
11:31 ET100111.695
11:33 ET325111.5249
11:38 ET600111.67
11:42 ET200111.63
11:45 ET953111.705
11:47 ET1624111.67
11:49 ET1996112.025
11:51 ET419111.895
11:54 ET775112.07
11:58 ET200112.16
12:00 ET300112.3194
12:02 ET718112.19
12:09 ET100112.125
12:18 ET600112.35
12:23 ET100112.15
12:27 ET1520112.525
12:30 ET1346112.44
12:32 ET100112.43
12:34 ET300112.28
12:36 ET100112.48
12:39 ET100112.51
12:41 ET373112.26
12:43 ET100112.5
12:45 ET600112.37
12:48 ET600112.2375
12:52 ET306112.265
12:56 ET219112.24
12:59 ET200112.31
01:01 ET253112.2
01:03 ET158112.32
01:08 ET229112.305
01:10 ET6100112.35
01:12 ET100112.5
01:14 ET600112.565
01:15 ET2020112.585
01:19 ET200112.58
01:26 ET100112.59
01:28 ET100112.595
01:30 ET626112.69
01:32 ET1260112.84
01:39 ET100112.67
01:46 ET300112.82
01:50 ET600112.975
01:57 ET758112.86
02:02 ET800112.695
02:04 ET540112.73
02:09 ET100112.7
02:11 ET300112.91
02:18 ET200113.05
02:20 ET659113.485
02:22 ET100113.44
02:24 ET515113.55
02:26 ET322113.408
02:29 ET534113.4372
02:31 ET1161113.43
02:33 ET429113.61
02:38 ET2140113.12
02:42 ET443113.03
02:44 ET300112.945
02:45 ET219112.94
02:47 ET204112.83
02:49 ET100112.73
02:51 ET234112.83
02:54 ET4639112.76
02:56 ET100112.765
02:58 ET900112.855
03:00 ET240112.825
03:02 ET500112.87
03:05 ET2579112.74
03:09 ET100112.79
03:14 ET282112.78
03:18 ET1312112.82
03:20 ET100112.77
03:21 ET100112.795
03:23 ET200112.815
03:25 ET600112.83
03:27 ET301112.75
03:30 ET316112.99
03:32 ET800112.83
03:36 ET478112.83
03:38 ET100112.67
03:39 ET200112.71
03:41 ET500112.79
03:43 ET3564112.62
03:45 ET500112.61
03:48 ET1016112.76
03:50 ET200112.695
03:52 ET1229112.89
03:54 ET2023112.64
03:56 ET1858112.39
03:57 ET5520112.46
03:59 ET7991112.51
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesGKOS
Glaukos Corp
5.6B
-39.1x
---
United StatesSTVN
Stevanato Group SpA
5.1B
31.2x
---
United StatesLNTH
Lantheus Holdings Inc
5.5B
12.5x
+35.30%
United StatesRGEN
Repligen Corp
6.9B
487.9x
+15.08%
United StatesMMSI
Merit Medical Systems Inc
4.8B
47.5x
+14.05%
United StatesPEN
Penumbra Inc
6.8B
72.5x
+65.82%
As of 2024-06-26

Company Information

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. It develops novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders and retinal disease. Its product candidates include Micro-Invasive Glaucoma Surgery products that involve the insertion of a micro-scale device designed to reduce intraocular pressure (IOP) by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma and procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce IOP by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time. Its products include transdermal pharmaceuticals that are applied to the eyelid and designed to treat glaucoma, dry eye, presbyopia and other ocular surface diseases and disorders and micro-invasive, bio-erodible sustained release drug delivery implants to improve the vision of patients.

Contact Information

Headquarters
1 GLAUKOS WAYALISO VIEJO, CA, United States 92656
Phone
949-367-9600
Fax
949-367-9984

Executives

Chairman of the Board, Chief Executive Officer
Thomas Burns
President, Chief Operating Officer
Joseph Gilliam
Chief Financial Officer, Senior Vice President
Alex Thurman
Chief Development Officer
Tomas Navratil
Lead Independent Director
Mark Foley

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$5.6B
Revenue (TTM)
$326.4M
Shares Outstanding
50.4M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.05
EPS
$-2.88
Book Value
$9.40
P/E Ratio
-39.1x
Price/Sales (TTM)
17.3
Price/Cash Flow (TTM)
---
Operating Margin
-41.29%
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.